Influence of phosphocreatine on serum N end B type natriuretic peptide and cardiac function in patients with congestive heart failure
10.3760/cma.j.issn.1008-6315.2015.08.008
- VernacularTitle:磷酸肌酸对充血性心力衰竭患者血浆氨基末端B型脑钠肽前体及心功能的影响
- Author:
Jing YANG
- Publication Type:Journal Article
- Keywords:
Phosphocreatine;
Congestive heart failure;
N end B type natriuretic peptide;
Cardiac function
- From:
Clinical Medicine of China
2015;31(8):701-703
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the influence of phosphocreatine on serum N end B type natriuretic peptide(NT-proBNP) and cardiac function in patients with congestive heart failure (CHF).Methods Ninetysix patients with CHF were randomly divided into the control group (n =47) and research group (n =49).The patients of the control group were given conventional therapy for treating CHF while the research group were given phosphocreatine based on treatment of the control group,and the course was 4 weeks.The total effective rate and left ventricular end diastolic diameter (LVEDD),left ventricular end systolic diameter (LVESD),left ventricular ejection fraction(LVEF) and NT-proBNP of pretherapy and post-treatment between the two groups were compared.Results There were no statistically significant differences about LVEDD,LVEDD,LVEF and BNP between the two groups (all P＞ 0.05);After treatment,LVEDD in the control group and the observation group patients were (53.5±5.6) mm,(46.4±4.5) mm,LVESD were ((39.9±5.3) mm,(34.6±4.8) mm and NT proBNP were (495.8±42.2) ng/L,(374.4±38.4) ng/L,significantly lower than before treatment ((58.3±6.4) mm,(58.4±6.8) mm;(48.4±6.3) mm,(48.7±6.2) mm;(875.4±64.8) ng/L,869.2 ± ±67.5) ng/L),and LVEF was higher than before treatment significantly (observation group by (35.8±3.2)％ rose to (52.6± 5.2) ％;control group by (36.4± 3.3) ％ rose to (44.5 ± 4.2) ％),and the observation group compared with the control group,the difference was statistically significant(P＜0.05).The total effective rate of research group was evidently higher than that of control group,the difference was statistically significant(93.8％ (45/49) vs.75.0％(36/47);x2=6.836,P=0.037).Conclusion Phosphocreatine can effectively strengthen the heart systolic functionincrease,LVEF,the serum NT-proBNP and enhance the total effective rate of patients with congestive heart failure.
